What was MEI Pharma’s price range in the past 12 months?
MEI Pharma lowest share price was $3.23 and its highest was $6.83 in the past 12 months.
What is MEI Pharma’s market cap?
Currently, no data Available
When is MEI Pharma’s upcoming earnings report date?
MEI Pharma’s upcoming earnings report date is May 09, 2024 which is in 12 days.
How were MEI Pharma’s earnings last quarter?
MEI Pharma released its earnings results on Feb 13, 2024. The company reported -$1.66 earnings per share for the quarter, missing the consensus estimate of -$1.413 by -$0.247.
MEI Pharma pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. See more information on MEI Pharma dividends here
What is MEI Pharma’s EPS estimate?
MEI Pharma’s EPS estimate is -$1.49.
How many shares outstanding does MEI Pharma have?
MEI Pharma has 6,662,857 shares outstanding.
What happened to MEI Pharma’s price movement after its last earnings report?
MEI Pharma reported an EPS of -$1.66 in its last earnings report, missing expectations of -$1.413. Following the earnings report the stock price went down -4.442%.
Which hedge fund is a major shareholder of MEI Pharma?
Among the largest hedge funds holding MEI Pharma’s share is Carlson Capital LP. It holds MEI Pharma’s shares valued at 429K.
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.